Lorlatinib ‘highly effective option’ for certain NSCLC patients
A head-to head trial shows it might be particularly effective in preventing intracranial progression, researchers say
AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.
Patients with advanced ALK-rearrangement positive non-small cell lung cancer (NSCLC) are likely to have significantly less disease progression if they are prescribed lorlatinib first line rather than crizotinib, a head-to-head trial shows.
Results of a pre-planned interim analysis of the Australian-led CROWN study were presented at the European Society for Medical Oncology (ESMO) virtual congress 2020.
Nearly 300 patients from 23 countries were randomised to receive either lorlatinib (100mg once daily) or crizotinib (250mg twice daily), Professor Benjamin Solomon of the Peter MacCallum Cancer Centre in Melbourne, told delegates.
